Dose-Response Relationships

DRC Basics & Curve Types - Dose Makes the Difference

• Dose: Amount of drug. Response: Effect observed.
• Dose-Response Relationship: Correlates dose with effect magnitude.
• Graded Response:
  • Effect intensity varies with dose in an individual.
  • Example: Blood pressure change.
  • Curve: Hyperbolic (linear dose) or sigmoid (log dose).
• Quantal Response:
  • All-or-none effect in a population (e.g., sleep/cure).
  • Shows frequency of response.
  • Curve: Typically sigmoid.
• DRC Shapes (General):
  • Hyperbolic: Response vs. linear dose.
  • Sigmoid (S-shaped): Response vs. log dose; for $ED_{50}$, $E_{max}$ analysis.

⭐ Graded dose-response curves depict the intensity of effect in an individual, while quantal curves show the frequency of response in a population.

Graded Dose-Response Curves - Efficacy vs. Might-acy

• Graded DRCs plot drug effect (response) against dose or concentration.
• Efficacy ($E_{max}$): Maximum effect a drug can produce. Represents the drug's maximal therapeutic potential. Higher $E_{max}$ = ↑ efficacy.
• Potency ($EC_{50}$ or $ED_{50}$): Dose/concentration required to produce 50% of $E_{max}$. Lower $EC_{50}$/$ED_{50}$ = ↑ potency.
  • Primarily reflects drug-receptor binding affinity.
• Slope of DRC: Indicates the range of doses over which response changes; steep slope = narrow therapeutic window.
• 📌 Mnemonic: Potency = Position (on X-axis, Left is more potent); Efficacy = Effect (Max Y-axis value).

⭐ Efficacy (maximum effect) is often clinically more important than potency (amount of drug needed for an effect).

Quantal DRCs & Drug Safety - Safety Numbers Game

• Quantal DRCs: Dose vs. % population with all-or-none effect.
• Key Metrics:
  • $ED_{50}$: Effective dose in 50% of population.
  • $TD_{50}$: Toxic dose in 50% of population.
  • $LD_{50}$: Lethal dose in 50% (animals).
• Drug Safety Indices (Margin of Safety indicators):
  • Therapeutic Index ($TI$): $TI = \frac{TD_{50}}{ED_{50}}$ or $TI = \frac{LD_{50}}{ED_{50}}$.
    • 📌 TILE: Toxic Is Lethal / Effective.
    • Low $TI$ (narrow margin, requires monitoring): Warfarin, Lithium, Digoxin, Phenytoin, Theophylline.
    • 📌 "Warning: These Drugs Can Leak Poison".
  • Certain Safety Factor ($CSF$): $CSF = \frac{LD_1}{ED_{99}}$ (stricter; $LD_1$: lethal 1%, $ED_{99}$: effective 99%).

⭐ A higher Therapeutic Index indicates a wider margin of safety for a drug.

Receptor Interactions & Response Variation - Receptor Roulette

• Agonists: Bind & activate receptors.
  • Full: Elicits maximal response ($E_{max}$); high intrinsic activity.
  • Partial: Submaximal response; lower intrinsic activity. Can act as antagonist with full agonist.
  • Inverse: Opposite effect to agonist; reduces basal receptor activity.
• Antagonists: Bind receptors, block agonist. 📌 Competitive Right-shifts $EC_{50}$ ($E_{max}$ same); Non-competitive Lowers $E_{max}$ (NCLM).

  Type	$EC_{50}$	$E_{max}$	Overcome by ↑ Agonist?	Site of Action
  Competitive (Reversible)	↑ (Right shift)	Unchanged	Yes	Active
  Non-competitive	Unchanged/↑	↓ (Down shift)	No	Allosteric/Active
  Irreversible	Unchanged/↑	↓ (Down shift)	No (covalent bond)	Active

  ⭐ Competitive antagonists increase $EC_{50}$ (shift DRC right) but do not change $E_{max}$, while non-competitive antagonists decrease $E_{max}$ and may or may not change $EC_{50}$.

• Response Variation:
  • Spare Receptors: $E_{max}$ achieved with fractional receptor occupancy (e.g., insulin).
  • Tachyphylaxis: Rapid ↓ drug response on repeated dosing (acute tolerance; e.g., ephedrine).
  • Tolerance: Gradual ↓ drug effectiveness with chronic use.
  • Desensitization: ↓ Receptor responsiveness (e.g., downregulation, uncoupling).
  • Idiosyncrasy: Genetically determined abnormal drug reaction (e.g., G6PD deficiency).

High‑Yield Points - ⚡ Biggest Takeaways

• Graded Dose-Response Curves (DRCs) relate drug dose to effect intensity.
• Efficacy (Emax) is the maximum possible effect a drug can produce.
• Potency (ED50): dose for 50% of Emax; lower ED50 means higher potency.
• Quantal DRCs show population response (all-or-none) to varying doses.
• Therapeutic Index (TI) = TD50/ED50; a wider TI indicates greater drug safety.
• Spare receptors allow Emax with submaximal receptor occupancy.